Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | MMP13 | P45452 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CRHBP | P24387 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17468447 | 0.90 | ALDH1A1 (0.63) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL179085 | 0.87 | RAB9A (0.76) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL2937877 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL19278119 | 0.84 | ALDH1A1 (0.72) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL1709310 | 0.84 | HPGD (0.73) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL11744707 | 0.84 | HSD17B10 (0.70) | SMN1; SMN2HPGDHSD17B10ALDH1A1TDP1 | |
| SCHEMBL8843519 | 0.84 | CYP3A4 (0.61) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL13853513 | 0.84 | SMN1; SMN2 (0.69) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL14368079 | 0.84 | HPGD (0.76) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA | |
| SCHEMBL7322125 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2HPGDHSD17B10ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | claimed |
| EP-3568133-B1 | CELL-PROTECTIVE COMPOUNDS AND THEIR USE | ETH ZUERICH (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2020-02-27 | — | — | US | disclosed |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2019179890-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH ZURICH (CH) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543231-A1 | COMPOUNDS FOR TREATING CNS- AND NEURODEGENERATIVE DISEASES | ETH Zurich (CH) | 2019-09-25 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| WO-2008082487-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-4058607-A | DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES | AIRWICK INDUSTRIES, INC. (US) | 1977-11-15 | — | — | US | disclosed |
| US-3962415-A | Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer | AIRWICK INDUSTRIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | SMN1; SMN2 3657/4885HPGD 709/4885HSD17B10 2555/4885 |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | SMN1; SMN2 3178/4885HPGD 2052/4885HSD17B10 4670/4885 |
| US-10428068-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | SMN1; SMN2 2620/4885HPGD 719/4885HSD17B10 2955/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | SMN1; SMN2 2620/4885HPGD 719/4885HSD17B10 2955/4885 |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | SMN1; SMN2 2620/4885HPGD 719/4885HSD17B10 2955/4885 |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | SMN1; SMN2 2620/4885HPGD 719/4885HSD17B10 2955/4885 |
| US-20200062754-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | SMN1; SMN2 2620/4885HPGD 719/4885HSD17B10 2955/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | SMN1; SMN2 2620/4885HPGD 719/4885HSD17B10 2955/4885 |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | SMN1; SMN2 2620/4885HPGD 719/4885HSD17B10 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.